What should cannabis operators know about mergers and acquisitions?

We advise on mergers, acquisitions and spin-offs for cannabis operators on both the buy side and the sell side. These transactions take dedicated time and specialized skills that internal teams, busy running the business, rarely have. Our work covers valuation, deal sourcing, due diligence, structuring, negotiation and post-close integration.

Yes, and preparation usually starts well before you go to market. We clean up the books so they hold up in buyer diligence, normalize historical earnings for owner adjustments and one-time items, position the business for the buyers who will value it most, address operational issues, and plan the tax structure to protect your after-tax proceeds.

Yes. We support acquisitions for geographic expansion, vertical integration, market share or diversification. That includes identifying or evaluating targets, financial and operational diligence that goes deeper than a standard audit review, testing whether the deal actually serves your strategy, valuation to support the offer, structuring, and integration planning.

Three things. Licenses often cannot be freely transferred, so the structure must allow for regulatory review that can add months. 280E treatment of the combined business depends on how the deal is structured, and a poor structure can leave the buyer worse off than the target was. And cannabis-focused capital is a smaller, more specialized pool than in most industries.

Where 280E applies, cost of goods sold is the main way to reduce federal taxable income, so the deal structure matters. The entity structure of the combined business determines how 280E applies going forward. The allocation of purchase price among assets affects inventory basis and future cost of goods sold. And the target's prior-year 280E positions become diligence items because they affect the buyer's exposure to historical liabilities.

Ownership changes usually require state regulatory review, and the rules vary. Some states require approval before any change of ownership, some allow closing subject to approval, and some set ownership thresholds or structures that trigger review. We build the licensing path into the deal structure from the start, because the wrong structure can stall a deal or create regulatory exposure.

Longer than in unregulated industries because of licensing review and cannabis-specific diligence. On the sell side, preparation before going to market often takes three to six months depending on how clean the business is. Marketing and negotiation typically add another three to six months, and closing can take additional months while licensing approval is obtained.

Everything a standard deal covers, plus cannabis-specific areas. Financial diligence covers quality of earnings, accuracy of historical statements, 280E positions on prior returns and the reliability of forecasts. Tax diligence extends to state cannabis taxes, sales and excise tax compliance, and prior audit exposure. Operational diligence covers seed-to-sale accuracy, license status, regulatory standing and whether the operation can deliver the forecast.

We value it on cannabis economics, not generic multiples from other industries, which can be wrong in either direction. That means accounting for 280E, the value of state licenses, cannabis capital costs and the target's competitive position in its markets. The work includes a defensible financial model, normalized historical performance and comparison against cannabis benchmarks where data exists.

It drives both valuation and structure decisions. On the sell side, the model supports the asking price and gives you a baseline for judging counter-offers. On the buy side, it tests deal economics under realistic assumptions, compares structure alternatives and stress-tests the deal against downside scenarios.

We prepare the negotiation strategy before talks begin, join discussions when you want senior advisor involvement, analyze term sheets and counter-offers as they arrive, and coordinate with your legal counsel on specific provisions. In cannabis, negotiation covers more than price: earnout structure, treatment of pre-close liabilities, the path through licensing approval and post-close arrangements.

State-licensed medical cannabis moved to Schedule III on April 28, 2026 (the order is being challenged in court). The DEA has so far registered only medical-only dispensaries, and the IRS hasn't said whether 280E relief depends on that registration, so medical-only operators are in the clearest position, while relief for operators with both medical and adult-use licenses is unresolved. Adult-use cannabis remains Schedule I pending the DEA administrative law judge's recommendation, so 280E still applies to it. In a deal, that means diligence and valuation must separate medical and adult-use activity and account for the risk that the medical change is reversed in court. Our cannabis rescheduling tracker has the current status.

We stay through integration, because that is where many deals succeed or fail. For cannabis deals this means bringing the combined financial reporting into one consistent, 280E-aware structure, integrating seed-to-sale and compliance processes, aligning operating processes across the formerly separate businesses, and managing the team dynamics that decide whether the deal thesis is realized.

Yes. Spin-offs are common in cannabis because many operators hold businesses that no longer belong together, whether from pre-license decisions, acquisitions that never integrated, or a change in strategy. We analyze which assets to separate, structure the separation to limit tax and regulatory friction, and support both the parent and the new entity through the transition.

Contact us for a confidential conversation about what you are considering, the timeline, the expected size of the deal and the help you need. We handle these discussions carefully because M&A plans are sensitive for employees, other stakeholders and regulators. We then propose a scope with the senior advisor leading the work, a timeline and a fee.